Appleseed Fund, an investment management company released its second quarter 2024 investor letter. A copy of the same can be downloaded here. The fund’s Investor Class generated an absolute return of 17.36% over the 6 months that ended March 31, 2024, compared to the Morningstar Global Small/Midcap Index’s 18.46% return. Appleseed Fund was positioned for an inflationary, slow-growth environment for most of the previous year. The cautious position of the Appleseed Fund prevented investment gains even while inflation levels have been lowering and the stock market has been raging since the end of 2022. In addition, Appleseed’s lack of exposure to Magnificent Seven limited returns. In addition, please check the fund’s top five holdings to know its best picks in 2024. Appleseed Fund highlighted stocks like Humana Inc. (NYSE:HUM), in the second quarter 2024 investor letter. Humana Inc. (NYSE:HUM) offers medical and specialty insurance products. Humana Inc.’s (NYSE:HUM) one-month return was 4.50%, and its shares lost 15.92% of their value over the last 52 weeks. On July 8, 2024, Humana Inc. (NYSE:HUM) stock closed at $370.43 per share with a market capitalization of $44.167 billion. Appleseed Fund stated the following regarding Humana Inc. (NYSE:HUM) in its Q2 2024 investor letter: "Appleseed Fund added three new names to the portfolio in the past six months: Humana Inc. (NYSE:HUM), AGNC Investment Corp. (AGNC), and Cameco Corporation (CCJ). Humana is one of several U.S. large managed care organizations and is primarily focused on government health insurance. Humana’s share price has fallen over 40.0% from post-COVID highs due to the recent emergence of elevated medical loss ratios. In our view, Humana’s stock has been severely punished and the stock was quite attractive at the time when Appleseed Fund took a position." A closeup of an elderly patient happily receiving a specialty healthcare product. Humana Inc. (NYSE:HUM) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 74 hedge fund portfolios held Humana Inc. (NYSE:HUM) at the end of the first quarter which was 86 in the previous quarter. While we acknowledge the potential of Humana Inc. (NYSE:HUM) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. We discussed Humana Inc. (NYSE:HUM) in another article and shared the list of largest companies in the US. In its Q1 2024 investor letter, Artisan Value Fund expressed a positive outlook for Humana Inc. (NYSE:HUM) and added it in its portfolio. In addition, please check out our hedge fund investor letters Q2 2024 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
Here’s Why Appleseed Fund Added Humana (HUM) on Dip
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...